The present edit ion of t he Port uguese Journal of Pulmonology brings t o our knowledge t he st udy of Pegas et al, 1 in wich were ident i ed t he risk fact ors for respirat ory problems in school children (5-12 years) in Lisboa.
Besides t hem it st at es a very high prevalence of wheezing (43,3 %) and a allergic rhinit is (43.0 %) amongst t hese children. And t hat t his prevalence increased, in relat ion t o previous st udies.
In a recent ly published art icle 2 we called t he at t ent ion t o t he ast hma's problem. Why?
Because it is our convict ion t hat bronchial ast hma(s) has not had, in a recent past , which we should place since t he mid 90s of t he last cent ury, t he int erest and t he at t ent ion it deserves -and it needs-by t he several groups of healt h professionals.
This evidence has raised, in us, a quest ion about t he reason of t he loss of int erest in t his disease.
Was it because t he number of ast hmat ics, nowadays, is so low t hat it does not j ust ify our at t ent ion?
Or t hey cont inue t o be over 300 million worldwide -and about 700,000 wit h act ive ast hma in Port ugal -but t hey have already reached cont rol levels t hat please everyone-and specially t he pat ient s?
Was t he rising prevalence in developed count ries, which in some, exceeds 50 % per decade, reversed or st opped? Do t he populat ions -in part icular t he pat ient s and t heir families-have already reached levels of knowledge t hat enables t hem t he qualit y of life and well being t hey wish and t hey have t he right t o have?
Were t he cost s of t he illness, considerably, reduced? The answer t o t hese quest ions, which are only a brief example of t he many t hat ast hma cont inues t o rise, it is always... no! In our opinion t wo words summarize t he answer: t he fashion! The word fashion is, usually, associat ed wit h clot hing and all t he several element s t hat can compose it .
But we can also use it when referred t o a cert ain way of act ing, or t o a behaviour model, accept ed and shared by a group of people in a given t ime.
The accept ance of t he mode, or of t he behaviour model, can have mult iple and diverse reasons and mot ivat ions. Some as simple as t he desire, or t he enj oyment , for what is new, or for becoming different .
But , as we know quit e well, somet imes t he wills and t he wishes can be induced and formed, in a relat ively easy way.
The fact is t hat t he chronic obst ruct ive pulmonary disease (COPD), unt il t hen an " obscured" ent it y acquired, over t he past 10-15 years, a st at us of prima donna, relegat ing bronchial ast hma t o a secondary place.
One must only read t he Revist a Port uguesa de Pneumologia (Port uguese Journal of Pulmonology) or flip t hrough t he pages of our congresses and meet ings, t o be fully aware of t he realit y.
The negat ive discriminat ion of bronchial ast hma goes as far as new drugs, an ult ra long act ing b 2 agonist , being only recommended in COPD. On t he accompanying informat ion it is expressly ment ioned t hat it has no indicat ion in bronchial ast hma! The hist ory of adrenergic drugs in ast hma, t hat have several millennia, 3 was sponged out . And t he same happened t o t he " recent " end of t he 60's of t he 20 t h cent ury, 2 when t here exist ed t he isoprenaline and t he orciprenaline -bot h being an import ant advance, but st ill wit h such a select ivit y t o t he b-recept or t hat so many problems induced in our ast hmat ic pat ient s. And t oA. Bugalho de Almeida cont rol of bronchial obst ruct ion of t he ast hmat ic, eit her t he permanent or t he episodic one.
Int erest ingly, over several decades, it was considered, and scient i cally j ust i ed, t hat t he rst line bronchodilat ors in COPD were t he ant icholinergics.
This new posit ion, or t his new fashion or behaviour, could have an underlying issue, relat ed t o t he evolut ionary perspect ives of t he diseases, not wit hst anding t he appropriat e t reat ment .
In ast hma what is expect ed is t hat t he vast maj orit y of t he pat ient s can achieve cont rol of t he disease over a short period of t ime -some mont hs.
And, from t he cont rol, t he maint enance t reat ment can only be an inhaled cort icost eroid and a b 2 agonist for relief t hat , ideally, will not be used.
It means t hat t he maj orit y for t he ast hmat ic pat ient s can have a qualit y of life and wellbeing -as it t hey would not suffer from any disease-wit h a minimal t herapy.
Unfort unat ely t his is not t rue for a very high percent age of pat ient s wit h COPD. This disease must be prevent ed. But once est ablished, t he prevent ion of it s progression is a maj or obj ect ive.
And it s t herapy is an add-on one. One must add ant icholinergics, b-agonist s, inhaled cort icost eroids, met hylxant hines, or, in a very near fut ure, an phosphodiest erase 4 inhibit or. Besides all t he ot her necessary measures.
And t he t reat ment will be prolonged ad perpet uam. Do t hese perspect ives " set t he t rends" ?!
